Kodiak Sciences
Logotype for Kodiak Sciences Inc

Kodiak Sciences (KOD) investor relations material

Kodiak Sciences UBS Global Biopharma Conference 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Kodiak Sciences Inc
UBS Global Biopharma Conference 2026 summary17 Nov, 2026

Tarcocimab efficacy and filing

  • DAYBREAK showed tarcocimab’s vision and fluid-control immediacy at least comparable to EYLEA; after four loading doses, over half of patients reached six-month dosing under stringent retreatment criteria.

  • Dosing was capped at six months, yet most patients did not meet retreatment criteria by that point; human half-life averaged 20 days, ranging from 10 to 50 days.

  • A revised formulation combining free and conjugated antibody was credited with supporting the results.

  • The BLA is being compiled across wet AMD, diabetic retinopathy and retinal vein occlusion, with filing targeted this year and potential approval in 2027.

  • Management cited an anti-VEGF market of about $15B; EYLEA HD was described as exceeding $8B and Vabysmo as trending above $5B, with expectations of $7B-$8B.

KSI-101 and MESI opportunity

  • MESI is macular edema associated with ocular inflammation; management estimated an initial U.S. addressable population of ~150,000 and described KSI-101 as a VEGF/IL-6 bispecific.

  • Phase III PEAK tests 5 mg and 10 mg against sham in severely affected cohorts; six monthly loading doses precede the week-24 endpoint, with mean vision change and 15-letter gain among key measures.

  • First top-line data are expected before Christmas; management expressed confidence and hopes for mean vision gains above 10 letters, while citing prior phase I/II responder rates above 50% in the sicker-patient group.

  • The second pivotal is almost fully enrolled, with completion expected this year and data targeted for May/June; a BLA is planned if development supports filing.

  • Management highlighted immediate fluid control in earlier studies and sees potential across MESI’s diverse inflammatory causes; it contrasted the program with Roche’s narrower anti-IL-6 approach and mixed phase III results.

Pipeline, commercial readiness and financing

  • KSI-501 had a positive DAYBREAK result in wet AMD and is being evaluated in phase III ALTO, where enrollment and randomization are progressing.

  • Antibodies are made in the U.S. and conjugates in Switzerland at a co-owned, dedicated facility; management said the facility can provide required commercial supply and is Swissmedic approved.

  • Management is building commercial capability for retina medicines, citing buy-and-bill potential, attractive pricing and an agile model for a focused U.S. specialty market.

  • A $70M ATM offering was completed recently; after the PEAK readout, management is considering a traditional financing intended to fund roughly the next 18 months, while emphasizing measured fundraising.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Kodiak Sciences earnings date

Logotype for Kodiak Sciences Inc
9th Annual Evercore ISI HealthCONx Conference1 Dec, 2026
Kodiak Sciences
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Kodiak Sciences earnings date

Logotype for Kodiak Sciences Inc
9th Annual Evercore ISI HealthCONx Conference1 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of retinal diseases. The company's research and development efforts are centered on novel biologics designed to treat conditions like age-related macular degeneration and diabetic eye diseases, which are major causes of blindness in the developed world. Kodiak's product pipeline includes advanced clinical candidates such as tarcocimab tedromer (KSI-301), which is designed to inhibit vascular endothelial growth factors. Additionally, the company is exploring other candidates targeting different mechanisms involved in retinal diseases. The company is headquartered in Palo Alto, California, and its shares are listed on the NASDAQ.